logo
After Wakefit, Verlinvest lines up Purplle and Veeba for IPOs

After Wakefit, Verlinvest lines up Purplle and Veeba for IPOs

Mint21 hours ago

One down, at least two more to go. After Verlinvest SA's portfolio company Wakefit Innovations Ltd filed for an IPO last week, the Belgium-based investment firm is queuing up beauty products platform Purplle and condiments maker Veeba for the public markets.
At least two more consumer startups from the investment firm's India portfolio could go public over the next two years, said Arjun Anand, executive director at Verlinvest.
Wakefit, which sells mattresses, beds, sofas, and home furnishings, filed for a ₹468.2 crore initial public offering last week.
Verlinvest is now preparing some of its mature investments, including Purplle and Veeba, for a public market debut, Anand told Mint, adding that both these companies have crossed ₹1,000 crore in annual revenue. Veeba and Purplle have not yet filed their financials for 2024-25.
While Wakefit is in an advanced stage of going public, Veeba and Purplle are likely to consider a listing over the next two years, Anand added.
'That's how the flywheel works," said Anand. 'Four to five mature companies will exit, three to four new ones will enter, and we will double down on the rest, just like we did with Blue Tokai."
Verlinvest invested a second tranche of $9 million in Blue Tokai Coffee Roasters this month, after putting in $20-21 million last year in the cafe and coffee brand. Mint reported in January that the firm was planning to participate in a fresh investment round in pet care brand Heads Up For Tails.
Verlinvest's other investments in India include yoghurt brand Epigamia and fertility services chain Ferty9. It previously also backed edtech platform Byju's.
As part of its plan to add 2-3 brands to its India portfolio every year, Verlinvest is actively scouting segments such as healthcare services, food and beverage, beauty, and experiential lifestyle for fresh investments, according to Anand.
Purplle, founded in 2012, has raised more than $500 million. In October, the beauty products retailer announced closing its Series F funding round at ₹1,500 crore (about $175,000), led by Abu Dhabi Investment Authority. In July last year, Purplle said it had raised ₹1,000 crore in a funding round led by an arm of ADIA at a valuation of $1.25 billion.
Its other investors include Blume Ventures, billionaire Azim Premji's Premji Invest, and Sharrp Ventures.
Veeba, also founded in 2012, sells sauces, dips, and other condiments. According to market research platform Tracxn, Veeba has raised $58.3 million from investors including Verlinvest, DSG Consumer Partners, and Saama Capital, and is currently valued at about ₹1,860 crore (about $217 million).
Purplle declined to comment on its IPO plans. Veeba didn't immediately reply to Mint's email.
Verlinvest's flywheel
Founded in 1995 by the family promoters of Belgium's AB InBev, the world's largest beer company, Verlinvest invests in consumer companies across Asia, Australia, Europe, and North America.
Unlike most private equity or venture capital funds, Verlinvest does not raise capital in cycles or return capital to limited partners, who are investors in PE and VC funds. Instead, it invests permanent capital from its founding shareholders and recycles gains from successful share sales into new investments.
'Our structure gives us flexibility on timelines. We are not bound by fund life," Anand said. 'We can keep putting more capital into a company over time, and exit when the market is ready."
Verlinvest's approach 'gives founders breathing room to build products and expand distribution networks genuinely, rather than chasing quick returns", said Roma Priya, founder of Burgeon Law, which counts both established and emerging businesses among its clients. 'That aligns well with India's consumer brand landscape, where long-term development often wins over fast scale."
India's public market has recently seen a pipeline of consumer-facing companies joining the IPO queue, following in the footsteps FSN E-Commerce Ventures Ltd (Nykaa) and Honasa Consumer (Mamaearth), both beauty products retailers, and electric scooter maker Ather Energy.
Eyewear retailer Lenskart, online meat seller Licious, electronics and wearables maker boAt, and stock-broking platform Groww are also planning to ride the resurgence in India's IPO market.
'India had the highest number of IPOs in the Asia-Pacific region recently, and over 90 companies have already filed to go public," said Priya. 'For global investors, this signals better exit opportunities driven by improved market sentiment, regulatory support, and a maturing base of Indian retail and institutional investors."
Per Wakefit's IPO filing, Verlinvest plans to offload about 10.19 million shares purchased at ₹82.67 apiece, signalling a lucrative investment exit for the firm.
Earlier this year, Verlinvest sold its remaining 12% stake in Sula Vineyards Ltd, which made its public market debut in December 2022, and trimmed its holding in Purplle from 17% to 10% through a secondary transaction involving the Abu Dhabi Investment Authority (ADIA).
'Sula returned over 4-5x on our investment, and Purplle also delivered extremely high returns," said Anand. 'Because the exits did well, we are in a strong position to reinvest and scale up."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ample Parks launches industrial and logistics park at Mahindra World City
Ample Parks launches industrial and logistics park at Mahindra World City

New Indian Express

time38 minutes ago

  • New Indian Express

Ample Parks launches industrial and logistics park at Mahindra World City

CHENNAI: Ample Parks, a joint venture between UK-based private equity firm Actis and Mahindra Lifespaces, has launched a 71-acre industrial and logistics park within the Domestic Tariff Area (DTA) of Mahindra World City (MWC), marking its foray into industrial real estate market. Backed by a planned investment of Rs 800 crore, the facility is the largest Grade-A industrial space within MWC's DTA and one of the few large-format developments of its kind in the region. The company plans to expand its land portfolio tenfold over the next five to seven years to build a pan-India platform. Located along the Oragadam-Maraimalai Nagar corridor, the park is designed to cater to industries including automotive, engineering, electronics and white goods. It offers 2.1 million sq ft of leasable area with both ready-to-move-in and built-to-suit options. Once fully operational, the park is expected to generate Rs 110 crore in annual revenue and over Rs 1,400 crore in a decade. It is also projected to create nearly 11,000 direct and indirect jobs. 'Ample Parks MWC is a future-ready ecosystem that integrates industrial, commercial, and logistics capabilities,' said Akash Rastogi, CEO and Director of Ample Parks. 'This is just the beginning, we intend to replicate this model across India's high-growth corridors.'

Global goods trade gains as tariff fears speed imports, WTO says
Global goods trade gains as tariff fears speed imports, WTO says

Time of India

timean hour ago

  • Time of India

Global goods trade gains as tariff fears speed imports, WTO says

Tired of too many ads? Remove Ads Global merchandise trade accelerated in the World Trade Organization's latest assessment, with a surge in imports tied to tariff stockpiling outweighing a slowdown in export WTO 's goods barometer rose to 103.5 in the first quarter, the highest level since August 2021, from the previous reading of 102.8, released in March, the Geneva-based organization said Thursday. The baseline of 100 indicates growth over the next quarter that's in line with medium-term orders were the only category in negative territory, the data showed. Increases were seen in air freight and container shipping along with rising demand for autos and electronics, the WTO President Donald Trump's higher taxes on goods entering the US — and threats to raise them even higher — have led companies to rush orders to avoid the extra costs.'This indicates strong trade volume growth in the first several months of 2025 possibly due to importers moving up purchases of goods in anticipation of higher tariffs in the future,' the report said. 'If so, trade growth should slow later in the year as sellers draw down inventories rather than importing more goods.'

Torrent Pharma share pops 4% on ₹25,689-cr JB Chem deal; analysts cautious
Torrent Pharma share pops 4% on ₹25,689-cr JB Chem deal; analysts cautious

Business Standard

timean hour ago

  • Business Standard

Torrent Pharma share pops 4% on ₹25,689-cr JB Chem deal; analysts cautious

Torrent Pharmaceuticals has signed a definitive agreement to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JBCP) at a fully diluted equity valuation of ₹25,689 crore. Tanmay Tiwary New Delhi Torrent Pharma share price today: Pharmaceutical company Torrent Pharmaceuticals shares were in focus on Monday, June 30, after the company announced a massive ₹25,689-crore deal to acquire JB Chemicals & Pharmaceuticals (JBCP). The Torrent Pharmaceuticals share surged as much as 3.89 per cent intraday to ₹3,474.60 apiece before paring gains. At last count, shares were trading 0.72 per cent higher at ₹3,368.35, even as the BSE Sensex remained flat around 84,003.81. The deal Torrent Pharmaceuticals has signed a definitive agreement to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JBCP) at a fully diluted equity valuation of ₹25,689 crore. The transaction, structured in two phases, begins with Torrent Pharmaceuticals acquiring 46.39 per cent stake via a share purchase agreement (SPA) at ₹1,600 per share, amounting to ₹11,917 crore. This will be followed by an open offer to buy up to 26 per cent from public shareholders at ₹1,639 per share. Additionally, Torrent Pharmaceuticals said that it aims to acquire 2.8 per cent of JB Chemicals and Pharmaceuticals' equity from certain employees at the same price offered to KKR. As part of the transaction, Torrent Pharmaceuticals and JB Chemicals and Pharmaceuticals will merge—JB Chemicals shareholders will receive 51 Torrent Pharmaceuticals' shares for every 100 JB Chemicals and Pharmaceuticals shares held. The deal is now pending shareholder and Competition COmmission of India (CCI) approvals and is expected to close in six months. Brokerages' view Brokerages broadly see the deal as strategically major, though the near-term impact remains mixed. According to domestic brokerage firm Motilal Oswal, the acquisition provides Torrent Pharmaceuticals with a diversified branded portfolio that includes several potential mega brands, a pan-India reach supported by a 2,800-strong medical representative field force, robust manufacturing infrastructure for multiple dosage forms, and access to a growing Contract Development and Manufacturing Organisation (CDMO) business driven by lozenges. The brokerage believes this acquisition is value accretive over the medium to long-term. Excluding the impact of JB Chemicals and Pharmaceuticals, Torrent Pharmaceuticals is expected to post a 12 per cent revenue, 14 per cent Ebitda, and 23 per cent PAT CAGR over FY25–27. The brokerage values the stock at 38x 12-month forward earnings, arriving at a target price of ₹3,430. However, it maintained a 'Neutral' rating, citing limited upside from current levels despite the deal's long-term merits. Those at Japan-based foreign brokerage firm Nomura noted that the move aligns with Torrent Pharmaceuticals' history of inorganic growth, particularly in India. The acquisition offers near-term cost synergies and potential long-term revenue synergies, especially as both firms have a dominant presence in the Cardiac and Gastro segments. However, it flagged concerns around execution risks given the unprecedented size of this deal for Torrent. Unlike past acquisitions, valuation premiums are higher, and there's limited headroom for operational improvement as JBCP is already a well-run business with strong market share in key products. In the near-term, the acquisition could be earnings dilutive, especially when factoring in higher interest and amortisation costs. Excluding amortisation, the deal may be marginally EPS accretive—if merged using Torrent stock. Thus, Nomura maintained a 'Neutral' rating on Torrent Pharmaceuticals with a target price of ₹3,580, based on 25x FY27 Ebitda of ₹4,850 crore. The stock currently trades at 26.1x one-year forward Ebitda. While analysts are mixed on the immediate financial impact, the Street appears optimistic about Torrent Pharmaceuticals' long-term strategic play in scaling up its domestic and international presence through this acquisition.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store